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Expression of Myoglobin in Human Cancers
Myoglobin plays important roles in both transporting ox-
ygen and scavenging free radicals in myocytes. Flonta et
al (Am J Pathol: 201–206) hypothesized that epithelial
cancers may also express myoglobin to survive condi-
tions associated with tumor growth such as hypoxia and
metabolism of reactive oxygen species. Indeed, human
epithelial tumors, including breast, lung, ovary, and colon
carcinomas, expressed high levels of myoglobin at early
stages of development. In addition, myoglobin was in-
duced in cell lines subjected to hypoxia, oxidative stress,
and mitogenic stimulation. Myoglobin expression in car-
cinomas may therefore protect against the stresses of
tumor growth.
Galgt2 Therapy for Muscular Dystrophy
Surrogate gene therapies for muscular dystrophy have
limited applicability across different models of dystrophic
disease. In disease models with decreased expression of
either dystrophin or laminin, overexpression of the glyco-
syltransferase galgt2, which alters the expression and
properties of proteins expressed in skeletal muscle, less-
ens the symptoms of muscular dystrophy. Xu et al (Am J
Pathol 174:235–247) examined the effects of galgt2 over-
expression in a mouse model of limb girdle muscular
dystrophy 2D. Overexpression of galgt2 in -sarcoglycan-
deficient mice resulted in reduced levels of myofiber dam-
age, and adeno-associated virus-mediated postnatal
expression of galgt2 protected myofibers from damage.
Increasing galgt2 expression may therefore have therapeu-
tic benefits in a broad range of muscular dystrophies.
Endothelin-1 Inhibition in Alzheimer’s Disease
A peptide, which accumulates in the brain of Alzhei-
mer’s disease patients, is thought to lead to vasoconstric-
tion and reduction of cerebral blood flood. Endothelin
converting enzyme-2 (ECE-2) may contribute to cerebro-
vascular dysfunction by converting the inactive precursor
“big endothelin” to the vasoconstrictor endothelin-1. To
determine whether ECE-2 plays a role in the vasocon-
striction seen in Alzheimer’s disease, Palmer et al (Am J
Pathol: 262–270) examined the neural expression of
ECE-2 in patients with Alzheimer’s disease and vascular
dementia compared with non-demented control patients.
ECE-2 levels were elevated in the temporal neocortex of
patients with Alzheimer’s disease but not vascular de-
mentia. Exposure of a neuroblastoma cell line to A re-
sulted in up-regulation of ECE-2 after 24 hours. These
data indicate that ECE-2 levels are up-regulated in re-
sponse to A and may cause the decrease in cerebral
blood flow observed in Alzheimer’s disease.
Stromal PDGFR (Platelet-Derived Growth
Factor  Receptor) Expression Correlates with
Negative Breast Cancer Prognosis
PDGF  and  receptors are involved in multiple stages
of cancer cell growth; however, the contribution of pos-
sible stromal expression remains unclear. Paulsson et al
(Am J Pathol: 334–341) characterized PDGF  and 
receptor expression on tumor vessel-associated peri-
cytes and tumor fibroblasts in lymphoma and in colon,
ovarian, prostate, lung, and breast cancers. They found
that PDGF  and  receptors were independently regu-
lated in the stroma of the tumor types tested, with
PDGFR more frequently expressed on tumor fibroblasts.
Colon and prostate tumors expressed the highest stromal
levels of PDGFR. In breast cancer, PDGFR expression is
associated with histological grade, tumor cell proliferation,
estrogen receptor expression status, and HER2 status. In
addition, stromal PDGFR expression in premenopausal
breast cancer patients significantly correlated with negative
prognosis. These data highlight the importance of examin-
ing stromal as well as malignant cell expression of PDGF
receptors in disease prognosis.
Gastrin and Helicobacter-Associated Gastric
Cancer
Helicobacter pylori, a major cause of gastric cancer, in-
duces chronic gastritis that leads to atrophy, dysplasia,
and finally gastric carcinoma. The mucosal growth factor
gastrin is elevated in response to Helicobacter infection,
and overexpression of gastrin in a mouse model causes
gastric cancer. However, gastrin-deficient mice have in-
creased levels of gastric antral tumors. To reconcile this
apparent disparity, Takaishi et al (Am J Pathol: 365–375)
examined the contribution of Helicobacter spp infection to
gastric cancer in hypergastrinemic, gastrin-deficient, and
wild-type mice of similar backgrounds. By 18 months after
infection, hypergastrinemic and wild-type mice had severe
atrophic gastritis and corpus dysplasia, whereas gastrin-
deficient mice had severe gastritis but no corpus dysplasia.
However, gastrin-deficient and wild-type mice had antral
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dysplasia, whereas hypergastrinemic mice did not exhibit
antral pathology. Gastrin, therefore, may have distinct ef-
fects between the gastric corpus and antrum and may play
a key role in gastric corpus carcinogenesis.
Carbon Monoxide Prevents Arterial Thrombosis
Heme oxygenase-1 (HO-1), which produces iron, biliverdin,
and carbon monoxide (CO) during the process of heme
degradation, is up-regulated in inflamed or injured tissues
and is thought to play a cytoprotective role in vivo. Although
high levels of CO are toxic, the low levels produced from
heme degradation may contribute to the cytoprotective
effects of HO-1. To determine whether HO-1 and CO
can protect against arterial thrombosis, Chen et al
(Am J Pathol: 422–429) examined platelet aggregation
in murine aortic allograft recipients. The absence of
HO-1 in aortic allograft recipients resulted in significant
mortality due to arterial thrombosis. However, treating
HO-1-deficient recipients with a CO-releasing mole-
cule significantly reduced platelet aggregation and im-
proved graft recipient survival. Therefore, systemic HO-
1/CO plays a key role in protecting against arterial thrombosis
in murine aortic allograft recipients.
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